Arterial Thromboembolism
0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
BayerLEVERKUSEN, Germany
1 programLong-term Active Surveillance Study for Oral Contraceptives (LASS)N/A1 trial
Active Trials
LeMaitre VascularAustralia - Docklands
1 programTufTex Single Lumen Embolectomy CatheterN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
LeMaitre VascularTufTex Single Lumen Embolectomy Catheter
BayerLong-term Active Surveillance Study for Oral Contraceptives (LASS)
Clinical Trials (2)
Total enrollment: 58,303 patients across 2 trials
A PMCF Study to Confirm the Performance and Safety of the LeMaitre® TufTex Single Lumen Embolectomy Catheter
Start: Jan 2022Est. completion: Jun 2027
N/ARecruiting
Long-term Active Surveillance Study for Oral Contraceptives (LASS)
Start: Feb 2001Est. completion: Dec 201158,303 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 58,303 patients
2 companies competing in this space